S2P.F SIMCERE PHARMAC. GRP LTD
- Market cap
- EUR 3.14B
- P/E
- 17.6x
- P/B
- 2.44x
- ROE
- 14.3%
- Dividend yield
- 1.90%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is S2P.F undervalued?
Graham numberS2P.F trades 38.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SIMCERE PHARMAC. GRP LTD fundamental analysis
No fundamental analysis for SIMCERE PHARMAC. GRP LTD yet.
SIMCERE PHARMAC. GRP LTD stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor f…
Full company profileSIMCERE PHARMAC. GRP LTD financial statements
SIMCERE PHARMAC. GRP LTD annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 5.00B | 6.32B | 6.61B | 6.64B | 7.73B |
| Gross Profit | 3.92B | 5.00B | 4.98B | 5.32B | 6.31B |
| Operating Income | 196M | 545M | 700M | 1.09B | 1.39B |
| EBITDA | - | 1.20B | 1.08B | 1.22B | 1.99B |
| Net Income | 1.51B | 931M | 715M | 722M | 1.34B |
| EPS | 0.57 | 0.35 | 0.27 | 0.29 | 0.52 |
| Balance Sheet | |||||
| Total Assets | 10.2B | 10.8B | 10.9B | 11.5B | 14.7B |
| Total Liabilities | 3.70B | 3.64B | 3.63B | 4.44B | 5.31B |
| Shareholders' Equity | 6.44B | 7.13B | 7.22B | 7.07B | 9.41B |
| Cash & Short-term Investments | 973M | 1.66B | 2.01B | 1.94B | 3.51B |
| Cash Flow | |||||
| Operating Cash Flow | -202M | 1.35B | 151M | 1.39B | 2.01B |
| Capital Expenditure | 209M | 678M | 980M | 763M | 862M |
| Free Cash Flow | -411M | 676M | -829M | 629M | 1.15B |
| Ratios | |||||
| ROE | 23.4% | 13.1% | 9.9% | 10.2% | 14.3% |
| ROA | 14.8% | 8.6% | 6.6% | 6.3% | 9.1% |
| Net Profit Margin | 30.1% | 14.7% | 10.8% | 10.9% | 17.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SIMCERE PHARMAC. GRP LTD dividends
- Dividend yield
- 1.90%
- Forward dividend
- 0.02 EUR
- Payout ratio
- 29.1%
- Ex-dividend date
- Jun 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 391M | 0.15 | 29.1% |
| 2024 | CNY 401M | 0.16 | 55.6% |
| 2023 | CNY 419M | 0.16 | 58.7% |
| 2022 | CNY 391M | 0.15 | 42.0% |
| 2021 | CNY 391M | 0.15 | 26.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns SIMCERE PHARMAC. GRP LTD
- Insiders 67.52%
- Institutions 12.22%
- Public & others 20.26%
- Shares outstanding 2.56B
- Free float 834M
SIMCERE PHARMAC. GRP LTD company profile
- Company name
- SIMCERE PHARMAC. GRP LTD
- Ticker
- S2P.F
- ISIN
- HK0000658531
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 7,064
- Fiscal year end
- December
- Address
- No. 699-18, Xuanwu Road, Nanjing, China, 210042
- Phone
- 86 25 8556 6666
- Website
- simcere.com
About SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clinical trials. The company also develops SIM0270, a new-generation oral SERD with blood-brain barrier penetration characteristics; Denlorlatinib; SIM0395, a BBB-penetrant inhibitor of the PI3K/mTOR pathway; and deuterated remdesivir hydrobromide dry suspension that are in Phase 3 clinical trial, as well as Sanbexin an injection new indication; Sanbexin a sublingual tablets; and SIM0278, a Fc fusion protein (IL2muFc) with an IL2 mutein of regulatory T cells that is in Phase 2 clinical trials. It develops SIM0237, an anti-PD-L1 monoclonal antibody fused with IL-15/IL15RXa sushi protein; Enzeshu, a suvemcitug for injection; SIM0500, a humanized trispecific antibody that targets GPRC5D/BCMA/CD3; SIM0508, a small molecule inhibitor; SIM0505, a CDH6-targeting ADC molecule; SIM0686, an ADC drug targeting FGFR2b; SIM0609, a new antibody-drug conjugate targeting CDH17; SIM0610, a bispecific antibody-drug conjugate; SIM0532, an oral, non-covalent pan-RAS inhibitor; SIM0323; and SIM0811, a small-molecule plasminogen allosteric activator that are in Phase 1 clinical trial. The company develops SIM0613; SIM0709; SIM0689; SIM0688; SIM0518; SIM0616; SIM0611; SIM0815; SIM0712; SIM0725; SIM0708; SIM0721; and SIM0722 that are in pre-clinical stage. It offers pharmaceutical ingredients; production support facility; consulting and technology; promotion; and property management. The company was founded in 1995 and is headquartered in Nanjing, China.
SIMCERE PHARMAC. GRP LTD management
10- Mr. Jinsheng RenCo-Founder & Chairman · born 1962
- Mr. Yushan WanCFO & Executive Director · born 1970
- Ms. Xi WangVP & Executive Director · born 1983
- Dr. Yunshu ZhouChief Executive Officer · born 1972
- Mr. Gaobo ZhouChief Investment Officer · born 1979
- Mr. Quanfu FengVice President of Marketing · born 1965
- Dr. Tamas Oravecz Ph.D.Senior VP & Chief Scientific Officer of Simcere Zaiming
- Dr. Aik Han GohSenior VP & Chief Medical Officer · born 1975
- Dr. Yongyu Wang M.D.Senior VP & Chief Medical Officer of Simcere Zaiming
- Dr. Wang Felix Ph.D.Senior VP & Secretary of the Party Committee